Search Our Scientific Publications & Authors

Signal Transduct Target Ther 2022 Aug 6;7(1):272. Epub 2022 Aug 6.

Department of Research and Development, Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam.

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. Read More

AIDS Res Ther 2022 Aug 6;19(1):38. Epub 2022 Aug 6.

Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, Rowland Hill St, London, NW3 2PF, UK.

Introduction: Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce.

Methods: Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann-Whitney U test and Chi-square test. Read More

J Neuroinflammation 2022 Aug 6;19(1):201. Epub 2022 Aug 6.

Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Background: Histone deacetylases (HDACs) are believed to exacerbate traumatic brain injury (TBI) based on studies using pan-HDAC inhibitors. However, the HDAC isoform responsible for the detrimental effects and the cell types involved remain unknown, which may hinder the development of specific targeting strategies that boost therapeutic efficacy while minimizing side effects. Microglia are important mediators of post-TBI neuroinflammation and critically impact TBI outcome. Read More

World Neurosurg 2022 Aug 3. Epub 2022 Aug 3.

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University. Shanghai, China; National Center for Neurological Disorders. Shanghai, China; Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration. Shanghai, China; Neurosurgical Institute of Fudan University. Shanghai, China; Shanghai Clinical Medical Center of Neurosurgery. Shanghai, China. Electronic address:

Background: A cavernous sinus dural arteriovenous fistula (CS-DAVF) is a form of abnormal arteriovenous communication that can be treated with endovascular embolization. Establishing an optimal access route should be based on vascular architecture. We reviewed 64 CS-DAVF patients who underwent endovascular embolization and reported the endovascular treatment approach selection and outcome. Read More

Int J Pharm 2022 Aug 3:122079. Epub 2022 Aug 3.

Department of Life and Environmental Sciences, Unit of Drug Sciences, University of Cagliari, Cagliari, Italy. Electronic address:

Pomalidomide (POM) is an FDA-approved immunomodulatory imide drug (IMiDs) an it is effectively used in the treatment of multiple myeloma. IMiDs are analogs of the drug thalidomide and they have been repurposed for the treatment of several diseases such as psoriatic arthritis and Kaposi Sarcoma. In recent years, IMiDs have been also evaluated as a new treatment for neurological disorders with an inflammatory and neuroinflammatory component. Read More